Ultralife (NASDAQ:ULBI) Shares Cross Above 200-Day Moving Average – Should You Sell?

Ultralife Corporation (NASDAQ:ULBI) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $6.81 and traded as high as $7.16. Ultralife shares last traded at $6.63, with a volume of 43,612 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of Ultralife in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Ultralife Stock Down 5.8%

The company has a market capitalization of $110.38 million, a PE ratio of 66.30 and a beta of 0.89. The company has a current ratio of 2.99, a quick ratio of 1.42 and a debt-to-equity ratio of 0.34. The firm has a 50 day simple moving average of $5.77 and a two-hundred day simple moving average of $6.81.

Ultralife (NASDAQ:ULBI) last released its quarterly earnings results on Monday, November 17th. The technology company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.21 by ($0.28). Ultralife had a return on equity of 1.66% and a net margin of 0.92%.The company had revenue of $43.37 million for the quarter, compared to analysts’ expectations of $53.00 million.

Insider Buying and Selling

In other Ultralife news, Director Bradford T. Whitmore bought 28,588 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was acquired at an average cost of $5.70 per share, with a total value of $162,951.60. Following the purchase, the director owned 1,235,631 shares in the company, valued at approximately $7,043,096.70. This represents a 2.37% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have acquired 56,750 shares of company stock worth $320,700. 40.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Ultralife

A number of institutional investors have recently modified their holdings of ULBI. Truffle Hound Capital LLC acquired a new stake in Ultralife in the 2nd quarter valued at about $2,245,000. RBF Capital LLC purchased a new stake in shares of Ultralife in the second quarter valued at about $2,020,000. Arrowstreet Capital Limited Partnership grew its position in shares of Ultralife by 210.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 219,018 shares of the technology company’s stock valued at $1,494,000 after purchasing an additional 148,542 shares during the last quarter. Teton Advisors LLC purchased a new position in shares of Ultralife during the 3rd quarter worth approximately $752,000. Finally, Russell Investments Group Ltd. raised its position in shares of Ultralife by 4,670.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 48,997 shares of the technology company’s stock worth $334,000 after purchasing an additional 47,970 shares during the last quarter. 30.68% of the stock is currently owned by hedge funds and other institutional investors.

Ultralife Company Profile

Ultralife Corporation (NASDAQ: ULBI) develops, manufactures and sells a broad range of energy and communications products for defense, medical, automotive and consumer electronics markets. The company operates through two primary segments: Power Systems and Communications Systems. In its Power Systems segment, Ultralife produces lithium-ion rechargeable cells and battery packs, primary lithium batteries, alkaline and rechargeable battery packs, chargers and battery accessories designed to meet demanding performance and safety requirements.